Jane Street’s ABVC BioPharma ABVC Stock Holding History

Jane Street’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,867	Closed	-$18K	–	11406
2025 Q4	$23.1K	Buy	+10,867	New	+$29.1K	﹤0.01%	10697
2022 Q4	–	Sell	-1,137	Closed	-$10K	–	9017
2022 Q3	$10K	Buy	+1,137	New	+$9.56K	﹤0.01%	9343

Other funds holding ABVC

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Jane Street's ABVC Position: Q1 2026 in Review

Jane Street sold out of ABVC BioPharma (ABVC) in Q1 2026, closing a stake of 10,867 shares — an estimated $18K sold.

Jane Street first reported a position in ABVC in Q3 2022 and held it in 2 quarters. The position peaked at $23.1K in Q4 2025. 13 funds tracked by Wall St. Rank hold ABVC as of Q1 2026.

Jane Street reported no remaining ABVC BioPharma position as of Q1 2026 after selling out during the quarter.
Jane Street sold 10,867 ABVC BioPharma shares in Q1 2026, an estimated $18K.
Jane Street first reported a position in ABVC BioPharma in Q3 2022 and held it in 2 quarters.
Jane Street's ABVC BioPharma position peaked at $23.1K in Q4 2025.
13 funds tracked by Wall St. Rank held ABVC BioPharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.